Skip to main content

COVID-19 Topic Center

Spinal Muscular Atrophy Expert Insights

First Report Managed Care
By Julie Gould Shephard Mpofu, MD, senior vice president and chief medical officer, Novartis Gene Therapies, discusses various trials—SPR1NT, LTFU, and RESTORE from Muscular Dystrophy Association Virtual Clinical and Scientific conference—that examined a treatment for spinal muscular atrophy (SMA…
First Report Managed Care
By Julie Gould  Wildon R Farwell, MD, MPH, global medical head of Neuromuscular Diseases, Biogen, breaks down the treatment challenges and unmet needs in spinal muscular atrophy (SMA), and reviews a recent SMA clinical trial.  What are the challenges in treating spinal muscular atrophy (SMA)?…
Back to Top